AIKI
AIkido Pharma Inc.
Set alert
52-week range unavailable
- Open
- 3.55
- Prev close
- 3.56
- Mkt cap
- 19.53M
- Vol
- 31.93K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.50
- High
- 3.66
- Forward P/E
- -2.37
- Beta
- 0.94
- Short ratio
- 2.31
- Inst. own
- 10.87%
- Dividend
- 0.00
- Ex-div date
- May 11, 1980
- Earnings
- Nov 10, 2022
- 50-d avg
- 4.35
- 200-d avg
- 4.30
- 1y target
- 16.00
Key statistics
- Market cap
- 19.53M
- Enterprise value
- -27.71M
- Trailing P/E
- 0.00
- Forward P/E
- -2.37
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.22
- EPS (TTM)
- -1.85
- Beta
- 0.94
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -16.31M
- Total cash
- 46.75M
- Total debt
- 743.00K
- Return on equity
- -18.01%
- Shares outstanding
- 5.49M
- Short % of float
- 1.39%
- 50-day average
- 4.35
- 200-day average
- 4.30
Analyst view
Consensus: buy
Next earnings
Nov 10, 2022
Expected Nov 10, 2022. Consensus EPS estimate -1.11.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 10, 2022 | Sep 1, 2022 | -0.77 | — | — | — |
| Aug 12, 2022 | Jun 1, 2022 | -0.68 | — | — | — |
| May 16, 2022 | Mar 1, 2022 | -0.34 | — | — | — |
| Mar 28, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
| Nov 10, 2021 | Sep 1, 2021 | -0.51 | — | — | — |
| Aug 11, 2021 | Jun 1, 2021 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2022 | HC Wainwright & Co. | main | — | Buy |
| Oct 11, 2021 | HC Wainwright & Co. | init | — | Buy |
About AIkido Pharma Inc.
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aikidopharma.com
News
- Why Is AIkido Pharma (AIKI) Stock Up 1,400%?
- Aikido Pharma (AIKI) Stock Price: 1-For-17 Reverse Split Goes Into Effect
- 81 Biggest Movers From Yesterday
- Stocks That Hit 52-Week Lows On Tuesday
- Stocks That Hit 52-Week Lows On Monday
- Stocks That Hit 52-Week Lows On Wednesday
- Trending Penny Stocks to Watch After Holiday Season
- 5 Top Penny Stocks To Watch Under $1 After CSCW Stock Explodes
- Best Penny Stocks to Buy Right Now? 3 to Watch This Month
- Best Penny Stocks to Buy in November? 3 You Need to Know About
Your note
Sign in to keep a note on AIKI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BLATTNER GREGORY JAMES | Director | Stock Award(Grant) | Aug 25, 2022 | 12,411 |
| DUDLEY ROBERT FREDERICK | Director | Stock Award(Grant) | Aug 25, 2022 | 12,411 |
| HAYES ANTHONY | Chief Executive Officer | Purchase | Dec 13, 2022 | 176,681 |
| LEDWICK TIM S | Director | Stock Award(Grant) | Aug 25, 2022 | 12,826 |
| LEMIRE PAUL | Director | Stock Award(Grant) | Aug 25, 2022 | 12,411 |
| VANDER ZANDEN ROBERT J | Director | Stock Award(Grant) | Aug 25, 2022 | 12,702 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 3.53% | 193,543 | 689.01K | Sep 29, 2022 |
| Two Sigma Advisers, LP | 1.58% | 86,700 | 308.65K | Sep 29, 2022 |
| Blackrock Inc. | 1.37% | 75,275 | 267.98K | Sep 29, 2022 |
| Dimensional Fund Advisors LP | 1.05% | 57,849 | 205.94K | Sep 29, 2022 |
| Two Sigma Investments, LP | 0.98% | 53,595 | 190.80K | Sep 29, 2022 |
| Geode Capital Management, LLC | 0.79% | 43,409 | 154.54K | Sep 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.02% | 111,013 | 395.21K | Sep 29, 2022 |
| Vanguard Extended Market Index Fund | 1.41% | 77,589 | 276.22K | Sep 29, 2022 |
| Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF | 0.46% | 25,457 | 90.63K | Jul 30, 2022 |
| Fidelity Extended Market Index Fund | 0.43% | 23,578 | 83.94K | Oct 30, 2022 |
| DFA U.S. Small Cap Series | 0.16% | 8,872 | 31.58K | Jul 30, 2022 |
| Fidelity Total Market Index Fund | 0.14% | 7,418 | 26.41K | Oct 30, 2022 |